The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
Congressionally Directed Medical Research Programs (CDMRP) -- Bone Marrow Failure Research Program -- Investigator-Initiated Research Award
The FY21 BMFRP Investigator-Initiated Research Award will offer two funding levels with different intent:
Funding Level 1 (FL1): To support studies that further develop ideas, expand upon key discoveries, and have the potential to make significant advances in research, patient care, and/or quality of life in the FY21 BMFRP Investigator-Initiated Research Award Focus Areas. Investigator-Initiated Research Award applications may involve basic, translational, and clinically oriented research, including studies in animal models, research with human anatomical substances, and research with human subjects, as well as correlative studies associated with an existing clinical trial; however, FL1 awards may not be used to support studies where the primary objective is a clinical trial. Multidisciplinary collaborations are encouraged.
Funding Level 2 (FL2): To support Investigational New Drug (IND)-enabling efforts. The BMFRP recognizes the scientific and financial challenges associated with advancing promising, potentially life-changing, therapeutic agents from the laboratory to clinical evaluation. Data related to lead compound characterization; formulation and stability; absorption, distribution, metabolism and excretion (ADME); dose/response; and toxicology are required before clinical trials can commence. The proposed studies under the FL2 IND-enabling efforts are expected to be empirical in nature, product-driven, and focused on the accumulation of data that will be used in an IND submission to the Food and Drug Administration (FDA) at the end of the period of performance. The intent of FL2 awards is to perform the necessary evaluation of promising therapies that will lead to clinical trials; however, clinical trials themselves are not supported by this mechanism. FL2 applications must address the FY21 BMFRP Focus Area “Find effective BMF treatments and cures”.
- Pre-Application Deadline: July 9, 2021
- Invitation to Submit an Application: August 2021
- Application Submission Deadline: Oct. 12, 2021
Areas of Interest
To meet the intent of the award mechanism, applications must address at least one of the FY21 BMFRP Investigator-Initiated Research Award Focus Areas listed below. Selection of the appropriate Focus Area is the responsibility of the applicant.
• Understand the causes and progression of BMF diseases
• Find effective BMF treatments and cures
Investigators at or above the level of Assistant Professor (or equivalent) may be named by the applicant organization as the PI on the application. Each investigator may be named on only one Investigator-Initiated Research Award application as an Initiating PI. An eligible PI, regardless of ethnicity, nationality, or citizenship status, must be employed by, or affiliated with, an eligible organization.
The anticipated direct costs budgeted for the entire period of performance for an FY21 BMFRP Investigator-Initiated Research Award FL1 award will not exceed $600,000, and the anticipated direct cost budgeted for the entire period of performance for an FY21 BMFRP InvestigatorInitiated Research Award FL2 award will not exceed $800,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.